Nuvation Bio Inc. Cost of Revenue
Nuvation Bio Inc. (NUVB) reported Cost of Revenue of $3.35 million for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-03.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2025-11-03
- Nuvation Bio Inc. cost of goods and services sold for the quarter ending 2025-09-30 was $3.35M, a 121.06% increase year-over-year.
- Nuvation Bio Inc. cost of goods and services sold for the quarter ending 2025-06-30 was $2.58M, a 91.24% increase year-over-year.
- Nuvation Bio Inc. cost of goods and services sold for the quarter ending 2025-03-31 was $2.09M.
- Nuvation Bio Inc. cost of goods and services sold for the quarter ending 2024-12-31 was $4.22M.
- Nuvation Bio Inc. cost of goods and services sold for fiscal 2024 was $7.08M.
- Nuvation Bio Inc. cost of goods and services sold for fiscal 2023 was $0.00.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2025-09-30 | $3.35M 10-Q · filed 2025-11-03 | $5.92M derived: sum of 2 quarters · filed 2025-11-03 | $8.02M 10-Q · filed 2025-11-03 | $12.23M derived: sum of 4 quarters · filed 2025-11-03 |
| 2025-06-30 | $2.58M 10-Q · filed 2025-08-07 | $4.67M 10-Q · filed 2025-08-07 | $8.89M derived: sum of 3 quarters · filed 2025-08-07 | $10.40M derived: sum of 4 quarters · filed 2025-11-03 |
| 2025-03-31 | $2.09M 10-Q · filed 2025-05-07 | $6.31M derived: sum of 2 quarters · filed 2025-05-07 | $7.83M derived: sum of 3 quarters · filed 2025-11-03 | $9.17M derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-12-31 | $4.22M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $5.73M derived: sum of 2 quarters · filed 2025-11-03 | $7.08M derived: sum of 3 quarters · filed 2025-11-03 | $7.08M 10-K · filed 2025-03-06 |
| 2024-09-30 | $1.51M 10-Q · filed 2025-11-03 | $2.86M derived: sum of 2 quarters · filed 2025-11-03 | $2.86M 10-Q · filed 2025-11-03 | |
| 2024-06-30 | $1.35M 10-Q · filed 2025-08-07 | $1.35M 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | $0.00 10-K · filed 2025-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |